Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 1.00 |
| ▸ | BCR | P11274 | 12/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.68 |
| ▸ | EGFR | P00533 | 5/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.67 |
| ▸ | PRKACG | P22612 | 1/20 | 0.67 |
| ▸ | PRKACB | P22694 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | BTK | Q06187 | 1/20 | 0.63 |
| ▸ | ITK | Q08881 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555505 | 1.00 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL2392 | 1.00 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| Ammonia Solution, Strong SCHEMBL4749564 | 0.99 | ABL1 (0.98) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| Hydrochloric Acid SCHEMBL2419016 | 0.99 | ABL1 (0.98) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL14938216 | 0.92 | ABL1 (0.85) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL3860532 | 0.91 | ABL1 (0.83) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL2575958 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL12320924 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL7601457 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL14041906 | 0.87 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | claimed |
| CN-110078706-B | Imatinib derivative and preparation method and application thereof | 浙江师范大学 | 2022-02-01 | — | — | CN | claimed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-11752152-B1 | Pharmaceutical formulations of imatinib and uses thereof | EXVASTAT LTD (GB) | 2023-09-12 | — | — | US | disclosed |
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-110078706-B | Imatinib derivative and preparation method and application thereof | 浙江师范大学 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752152-B1 | Pharmaceutical formulations of imatinib and uses thereof | ABL1, JAK2, ABL2 | ABL1 1/4885BCR 244/4885PRKCA 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.